Comparative Pharmacology
Head-to-head clinical analysis: LACTULOSE versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LACTULOSE versus SUFLAVE.
LACTULOSE vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Constipation: 15-30 mL (10-20 g) orally once daily, increased to 45-60 mL (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
250 mg intravenously every 12 hours.
None Documented
None Documented
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category C
Category C
Laxative
Laxative